Phase 1 Type 2 Diabetes Trial, Not Yet Recruiting NCT06670209 Sponsor: Gan and Lee Pharmaceuticals, USA Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 1 Type 2 Diabetes Trial, Not Yet Recruiting

NCT06670209
Not Yet Recruiting Phase 1

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are overweight or obese, of Chinese background, are willing to sign a consent form, can receive injections under the skin, fully understand what the trial involves including possible side effects, and are able to follow the rules set out in the trial plan.
  • People who are male or female, aged between 18 and 50 years old (inclusive) at the time of signing the consent form.
  • People who weigh at least 50 kg and have a Body Mass Index (BMI) between 24 and 33 kg/m² (inclusive) at the screening stage.
  • People who are capable of having children must have no plans for pregnancy or donating eggs or sperm from the time of signing the consent form until 3 months after the last dose, and must be willing to use effective contraception during that time; women who are capable of having children must not be breastfeeding and must have negative pregnancy test results at screening and at the visit before enrolling in the trial.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with a past or current history of heart, liver, kidney, digestive, breathing, nervous system, mental health, cancer, or other conditions that the trial doctor believes could affect how the study drug works in the body or how safety is assessed.
  • People with a history or current condition that raises health risks, such as low blood sugar episodes, past or current inflammation of the pancreas, pancreatic injury, symptoms related to the gallbladder, or gallstones that could put them at high risk of a serious gallbladder-related condition at the time of screening.
  • People with past or current conditions that significantly affect how the body absorbs, processes, or removes drugs — such as active stomach ulcers or bleeding, inflammatory bowel disease, abnormal stomach emptying (such as gastroparesis or a blocked stomach outlet), or long-term use (one week or more continuously) of medicines that affect how the gut moves, including but not limited to certain named medications (confirm with trial site).
  • People who have had a serious or unexplained infection in the 4 weeks before screening.
  • People who have had major surgery in the 6 months before screening, or who have surgery or a hospital stay planned during the trial period.
  • People with a history of drug misuse before screening, or who test positive for drug misuse at screening.
  • People who have used any nicotine-containing products in the 3 months before screening, or who test positive for nicotine in a urine test at screening.
  • People who the trial doctor considers unsuitable to participate for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 24 July 2026

Contact this trial

Phone: 010-80593549

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
Gan and Lee Pharmaceuticals, USA
Registry
ClinicalTrials.gov
Start date
30 October 2024
Est. completion
19 March 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Primary endpoints

Cmax,ss; AUC0-tau

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov